Form 4: Precision Biosciences CEO Michael Amoroso Awarded Over 200,000 Restricted Stock Units

Precision Biosciences' President and CEO, Michael Amoroso, was granted 203,390 restricted stock units, aligning his incentives with long-term company performance.

Summary

• Michael Amoroso, the President and CEO, and a Director of PRECISION BIOSCIENCES INC (DTIL), was the reporting person for this SEC Form 4 filing.
• On June 2, 2025, Mr. Amoroso acquired 203,390 Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
• The awarded RSUs will vest in three substantially equal annual installments, with the first vesting date commencing on February 17, 2026.
• Vesting is contingent upon Mr. Amoroso's continued service to Precision Biosciences through the applicable vesting dates.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to the CEO is a positive indicator of management's long-term commitment and alignment with shareholder interests, as the value of the award is tied to the company's stock performance. While not a direct financial gain for the company, it strengthens governance and incentive structures.

Positives

• The grant of restricted stock units to the President and CEO aligns management's long-term interests directly with those of the shareholders, as the value of the award is tied to the company's stock performance.
• This equity award serves as an incentive for the CEO to drive sustained growth and value creation for the company.

Future Outlook

The vesting schedule of the restricted stock units indicates a long-term commitment from the CEO, with the awards designed to incentivize performance over the next several years, beginning in February 2026.

Industry Context

This Form 4 filing is a standard disclosure of an executive equity award, a common practice across industries to align executive incentives with shareholder value. It does not provide broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of the CEO's interests with the long-term performance and value creation of the company.

Next Steps

• The restricted stock units will begin vesting in three substantially equal annual installments starting February 17, 2026, subject to the CEO's continued service.

Key Dates

Recommendation

Keywords

Precision Biosciences, DTIL, Michael Amoroso, Restricted Stock Units, RSU, Insider Transaction, SEC Form 4, Equity Award, CEO Compensation, Corporate Governance